Merck to Present New Data on MS Portfolio: Rebif, Mavenclad, and Evobrutinib at ECTRIMS 2017
- Important safety and immune cel analyses further characterize the selective immune reconstitution approach of Mavenclad;
<p>- Continued innovation with Rebif includes analysis of NEDA and use of MAGNIMS criteria in predicting clinical outcomes out to 15 years;
<p>- Pre-clinical data for investigational evobrutinib highlight potential role in patients with relapsing MS;
<p>- A total of 40 abstracts will be presented by lead investigators.
<p>- Continued innovation with Rebif includes analysis of NEDA and use of MAGNIMS criteria in predicting clinical outcomes out to 15 years;
<p>- Pre-clinical data for investigational evobrutinib highlight potential role in patients with relapsing MS;
<p>- A total of 40 abstracts will be presented by lead investigators.
- 18.10.2017, 15:48
- Kategoria: Zdrowie i styl życia
- Źródło: PR Newswire